218 related articles for article (PubMed ID: 22890844)
1. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus.
Rytinki M; Kaikkonen S; Sutinen P; Paakinaho V; Rahkama V; Palvimo JJ
Mol Cell Biol; 2012 Oct; 32(20):4195-205. PubMed ID: 22890844
[TBL] [Abstract][Full Text] [Related]
2. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
Kaikkonen S; Jääskeläinen T; Karvonen U; Rytinki MM; Makkonen H; Gioeli D; Paschal BM; Palvimo JJ
Mol Endocrinol; 2009 Mar; 23(3):292-307. PubMed ID: 19116244
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin 15d-PGJ(2) inhibits androgen receptor signaling in prostate cancer cells.
Kaikkonen S; Paakinaho V; Sutinen P; Levonen AL; Palvimo JJ
Mol Endocrinol; 2013 Feb; 27(2):212-23. PubMed ID: 23192983
[TBL] [Abstract][Full Text] [Related]
4. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability.
Yang N; Liu S; Qin T; Liu X; Watanabe N; Mayo KH; Li J; Li X
Cell Commun Signal; 2019 Nov; 17(1):153. PubMed ID: 31752909
[TBL] [Abstract][Full Text] [Related]
5. Nuclear mobility and activity of FOXA1 with androgen receptor are regulated by SUMOylation.
Sutinen P; Rahkama V; Rytinki M; Palvimo JJ
Mol Endocrinol; 2014 Oct; 28(10):1719-28. PubMed ID: 25127374
[TBL] [Abstract][Full Text] [Related]
6. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.
Toropainen S; Malinen M; Kaikkonen S; Rytinki M; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
Nucleic Acids Res; 2015 Jan; 43(2):848-61. PubMed ID: 25552417
[TBL] [Abstract][Full Text] [Related]
7. Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.
Mukherjee S; Thomas M; Dadgar N; Lieberman AP; Iñiguez-Lluhí JA
J Biol Chem; 2009 Aug; 284(32):21296-306. PubMed ID: 19497852
[TBL] [Abstract][Full Text] [Related]
8. SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner.
Sutinen P; Malinen M; Heikkinen S; Palvimo JJ
Nucleic Acids Res; 2014 Jul; 42(13):8310-9. PubMed ID: 24981513
[TBL] [Abstract][Full Text] [Related]
9. Analysis of androgen receptor SUMOylation.
Rytinki MM; Kaikkonen S; Sutinen P; Palvimo JJ
Methods Mol Biol; 2011; 776():183-97. PubMed ID: 21796528
[TBL] [Abstract][Full Text] [Related]
10. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
Zheng Z; Cai C; Omwancha J; Chen SY; Baslan T; Shemshedini L
J Biol Chem; 2006 Feb; 281(7):4002-12. PubMed ID: 16361251
[TBL] [Abstract][Full Text] [Related]
11. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR SUMOylation.
Wu R; Cui Y; Yuan X; Yuan H; Wang Y; He J; Zhao J; Peng S
Toxicol Lett; 2014 Sep; 229(2):405-13. PubMed ID: 25014244
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells.
Malinen M; Toropainen S; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
Mol Cell Endocrinol; 2015 Oct; 414():91-8. PubMed ID: 26219822
[TBL] [Abstract][Full Text] [Related]
13. SUMO-1, human male germ cell development, and the androgen receptor in the testis of men with normal and abnormal spermatogenesis.
Vigodner M; Ishikawa T; Schlegel PN; Morris PL
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1022-33. PubMed ID: 16352666
[TBL] [Abstract][Full Text] [Related]
14. The in vivo role of androgen receptor SUMOylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the proline/glycine residues of synergy control motifs.
Mukherjee S; Cruz-Rodríguez O; Bolton E; Iñiguez-Lluhí JA
J Biol Chem; 2012 Sep; 287(37):31195-206. PubMed ID: 22829593
[TBL] [Abstract][Full Text] [Related]
15. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).
Poukka H; Karvonen U; Janne OA; Palvimo JJ
Proc Natl Acad Sci U S A; 2000 Dec; 97(26):14145-50. PubMed ID: 11121022
[TBL] [Abstract][Full Text] [Related]
16. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription.
Nishida T; Yasuda H
J Biol Chem; 2002 Nov; 277(44):41311-7. PubMed ID: 12177000
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.
Yang Y; Tse AK; Li P; Ma Q; Xiang S; Nicosia SV; Seto E; Zhang X; Bai W
Oncogene; 2011 May; 30(19):2207-18. PubMed ID: 21242980
[TBL] [Abstract][Full Text] [Related]
18. Modeling truncated AR expression in a natural androgen responsive environment and identification of RHOB as a direct transcriptional target.
Tsai HC; Boucher DL; Martinez A; Tepper CG; Kung HJ
PLoS One; 2012; 7(11):e49887. PubMed ID: 23209612
[TBL] [Abstract][Full Text] [Related]
19. The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.
Chen ST; Okada M; Nakato R; Izumi K; Bando M; Shirahige K
J Biol Chem; 2015 Aug; 290(35):21713-23. PubMed ID: 26175158
[TBL] [Abstract][Full Text] [Related]
20. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
Ashikari D; Takayama K; Tanaka T; Suzuki Y; Obinata D; Fujimura T; Urano T; Takahashi S; Inoue S
Oncogene; 2017 Nov; 36(45):6272-6281. PubMed ID: 28692047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
